Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 10
Submit an article Journal homepage
181
Views
1
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes

Harilal PatelBioanalytical/Drug Metabolism and Pharmacokinetics Laboratory, Zydus Research Centre, Ahmedabad, India; ;Department of Chemistry, St Xavier's College (Autonomous), Gujarat University, Ahmedabad, India;
,
Nirmal DesaiDepartment of Chemistry, St Xavier's College (Autonomous), Gujarat University, Ahmedabad, India; Correspondence[email protected]
,
Prakash PatelBioanalytical/Drug Metabolism and Pharmacokinetics Laboratory, Zydus Research Centre, Ahmedabad, India;
,
Nirav ModiBioanalytical/Drug Metabolism and Pharmacokinetics Laboratory, Zydus Research Centre, Ahmedabad, India;
,
Krunal SoniBioanalytical/Drug Metabolism and Pharmacokinetics Laboratory, Zydus Research Centre, Ahmedabad, India;
,
Nitin DobariaPharmaceutical Technology Centre, Cadila Healthcare Limited, Ahmedabad, India
&
Nuggehally R. SrinivasBioanalytical/Drug Metabolism and Pharmacokinetics Laboratory, Zydus Research Centre, Ahmedabad, India;
show all
Pages 1202-1208 | Received 20 Sep 2018, Accepted 22 Oct 2018, Published online: 27 Dec 2018

References

  • Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32.
  • Burger DM, Smolders EJ, Schapiro J, et al. (2017). A call for a consortium for optimal management of drug-drug interactions in patient care. Clin Pharmacol Ther 102:391–94.
  • Chu V, Einolf HJ, Evers R, et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 37:1339–54.
  • Evans DC, O'Connor D, Lake BG, et al. (2003). Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31:861–9.
  • Gomez DY, Wacher VJ, Tomlanovich SJ, et al. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15–9.
  • Kassem AA. (2016). Formulation approaches of triptans for management of migraine. Curr Drug Deliv 13:882–98.
  • Kim YK, Shin K-H, Alderman J, et al. (2018). Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects. Drug Des Devel Ther 12:331–37.
  • Kimura S, Oshima K, Okuda S, et al. (2010). Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 45:1088–94.
  • Malcolm R. (1972). Influence of route of administration on drug availability. J Pharm Sci 61:70–4.
  • Mayans L, Walling A. (2018) Acute migraine headache: treatment strategies. Am Fam Physician 97:243–51.
  • Milton KA, Scott NR, Allen MJ, et al. (2002). Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 42:528–39.
  • Pea F, Baccarani U, Tavio M, et al. (2008). Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 42:1711–6.
  • RELPAX®, Package Insert. (2018). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf [last accessed 4 Sep 2018].
  • RELPAX, Pharmacology Review. (2018). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_Pharmr_P1.pdf [last accessed 18 Oct 2018]
  • RELPAX, Clinical Pharmacology and Biopharmaceutics review. (2018). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf [last accessed 18 Oct 2018]
  • Shah AK, Harris SC, Greenhalgh C, Morganroth J. (2002). The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 42:520–7.
  • Srinivas NR. (2009a). Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomed Chromatogr 23:451–4.
  • Srinivas NR. (2009b). Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?. Xenobiotica 39:193–6.
  • Srinivas NR. (2016). Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs R D 16:141–8.
  • US FDA. (2018). Bioanalytical method validation guidance for industry, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Biopharmaceutics. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf [last accessed 20 Sep 2018).
  • Vieira ML, Zhao P, Berglund EG, et al. (2012). Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther 91:700–8.
  • Xia YQ, Jemal M. (2009). Phospholipids in liquid chromatography/mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Commun Mass Spectrom 23:2125–38.
  • Youdim KA, Zayed A, Dickins M, et al. (2008). Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds asobjects of interaction. Br J Clin Pharmacol 65:680–92. DOI:10.1111/j.1365-2125.2007.03070.x.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.